See more : Veolia Environnement S.A. (VIE.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Alaunos Therapeutics, Inc. (TCRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alaunos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- UDS Group, Inc. (UDSG) Income Statement Analysis – Financial Results
- Geberit AG (GBERY) Income Statement Analysis – Financial Results
- S&S Healthcare Holding Ltd. (4198.TWO) Income Statement Analysis – Financial Results
- SRE Holdings Corporation (2980.T) Income Statement Analysis – Financial Results
- Saturn Oil & Gas Inc. (SOIL.TO) Income Statement Analysis – Financial Results
Alaunos Therapeutics, Inc. (TCRT)
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.00K | 2.92M | 398.00K | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Cost of Revenue | 4.80M | 2.76M | 740.00K | 1.13M | 629.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.80M | 163.00K | -342.00K | -1.13M | -629.00K | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Gross Profit Ratio | -95,960.00% | 5.58% | -85.93% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 16.28M | 25.02M | 49.64M | 52.70M | 38.33M | 34.13M | 45.08M | 157.79M | 106.79M | 32.71M | 42.85M | 83.45M | 57.08M | 12.91M | 4.56M | 17.25M | 18.99M | 10.39M | 5.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 773.14K | 8.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 120.00 |
| SG&A | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 120.00 |
| Other Expenses | 971.00K | 529.00K | -1.20M | 385.00K | 813.00K | 631.00K | 465.00K | 134.00K | 12.00K | -5.00K | -579.00K | -13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.39M | 0.00 | 0.00 | 486.00 | 42.51K | 74.14K |
| Operating Expenses | 29.47M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Cost & Expenses | 34.27M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.92M | 3.15M | 1.18M | 0.00 | 0.00 | 0.00 | 830.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.32M | 2.76M | 2.60M | 1.13M | 629.00K | 573.00K | 369.00K | 290.00K | 357.00K | 462.00K | 738.00K | 658.00K | 268.00K | 188.00K | 330.00K | 388.00K | 433.35K | 173.92K | 101.23K | 0.00 | 486.00 | 799.00 | 750.00 |
| EBITDA | -30.90M | -31.82M | -74.97M | -78.85M | -117.17M | -53.33M | -53.12M | -165.01M | -119.73M | -43.50M | -56.98M | -102.17M | -71.40M | -32.48M | -7.32M | -24.84M | -26.17M | -17.68M | -9.42M | -5.65M | -35.36K | -39.14K | -71.79K |
| EBITDA Ratio | -618,080.00% | -1,187.85% | -19,112.81% | 0.00% | 0.00% | -37,030.14% | -817.00% | -2,407.56% | -2,772.39% | -4,022.00% | -7,270.00% | -13,445.13% | -11,807.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,523.04% | -4,159.04% |
| Operating Income | -34.27M | -35.11M | -77.55M | -80.36M | 2.26M | -53.91M | -53.49M | -165.31M | -120.10M | -43.50M | -57.71M | -102.17M | -71.40M | -24.55M | -12.12M | -25.62M | -28.57M | -19.11M | -9.79M | -39.17K | -35.84K | -39.94K | -72.54K |
| Operating Income Ratio | -685,340.00% | -1,201.40% | -19,484.67% | 0.00% | 0.00% | -36,921.92% | -837.27% | -2,409.37% | -2,772.39% | -3,168.17% | -7,214.13% | -12,771.13% | -10,704.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Total Other Income/Expenses | -873.00K | -2.63M | -1.20M | 385.00K | -59.94M | 789.00K | -830.00K | 10.00K | 12.00K | 11.72M | 606.00K | 6.04M | 7.62M | -8.12M | 4.47M | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -35.14M | -37.73M | -78.75M | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | 0.00 | -17.86M | 0.00 | -39.17K | -35.84K | -39.94K | -72.54K |
| Income Before Tax Ratio | -702,800.00% | -1,291.24% | -19,786.68% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Income Tax Expense | 0.00 | -133.00K | -1.86M | -1.13M | 60.12M | -947.00K | 2.13M | 114.00K | -12.00K | -23.44M | -1.79M | -12.09M | -15.24M | 16.25M | -8.95M | -388.00K | -1.96M | -1.25M | -270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -35.14M | -37.60M | -76.89M | -78.85M | -177.92M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Net Income Ratio | -702,800.00% | -1,286.69% | -19,320.10% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| EPS | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.52 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| EPS Diluted | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.44 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| Weighted Avg Shares Out | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
| Weighted Avg Shares Out (Dil) | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 958.07K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
Why Alaunos Therapeutics Stock Sank Today
Investors appeared to take profits off the table after the biotech's positive news last week.
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September
HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development...
Why Alaunos Therapeutics Topped the Market on Tuesday
A specialty cancer therapy developed by the company shows some rather promising results.
These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)
Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).
Why Alaunos Therapeutics Stock Is Up Yet Again Today
Shorts appear to be moving to the sidelines ahead of an upcoming presentation.
Why Alaunos Therapeutics Stock Is Tumbling Today
The biotech's stock is giving back some of its recent gains.
Best Penny Stocks To Watch After Powell's Jackson Hole Speech
Penny stocks to watch with relative strength in the stock market today. The post Best Penny Stocks To Watch After Powell's Jackson Hole Speech appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Alaunos Therapeutics' Shares Jumped 48.9% This Week
The rise was part of an upswing that began earlier this year.
Why Alaunos Therapeutics Stock Was On Fire Today
The cell therapy company's shares have been crushing it this year.
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
HOUSTON, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer...
Source: https://incomestatements.info
Category: Stock Reports